Covid-19 (Temas de Saúde Pública)
OMS | Desigualdade vacinal prejudica a recuperação econômica global.
23 Jul, 2021 | 10:19hComunicado de imprensa: Vaccine inequity undermining global economic recovery – World Health Organization
Painel: Global Dashboard for Vaccine Equity
Comentários: Urgent need for COVID-19 vaccine equity – University of Oxford E COVID-19 Vaccine Inequity Undermines Global Economic Recovery – Health Policy Watch
Comentário no Twitter (fio – clique para saber mais)
COVID-19 vaccine inequity is undermining 🌍 economic recovery. 🆕WHO, @UNDP and @BlavatnikSchool Dashboard on #VaccinEquity finds that low-income countries would add $38B to their GDP forecast if they had the same vaccination rate as high-income countrieshttps://t.co/BsYF2eYL1G
— World Health Organization (WHO) (@WHO) July 22, 2021
Perspectiva | “Challenge Trials” com o SARS-CoV-2 (quando pessoas saudáveis são expostas deliberadamente ao virus, para fins de pesquisa) – Estabelecendo um modelo durante uma pandemia em evolução.
23 Jul, 2021 | 10:17hRelacionado: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (vários textos sobre o tema) E Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.
Como a variante Delta atinge sua disseminação ultrarrápida – “A carga viral é cerca de 1.000 vezes maior em pessoas infectadas com a variante Delta do que nos infectados com a cepa original do coronavírus, de acordo com estudo feito na China.”
23 Jul, 2021 | 10:15hHow the Delta variant achieves its ultrafast spread – Nature
O que são as variantes Delta, Gama, Beta e Alfa da Covid?
23 Jul, 2021 | 10:14hWhat are the Delta, Gamma, Beta and Alpha Covid variants? – BBC
Relacionado: Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”. E WHO renames COVID-19 variants with the Greek alphabet (i.e., Alpha, Beta, Gamma, etc), making them simple, easy to say and remember. The naming system aims to prevent calling COVID-19 variants by the places where they are detected, which is stigmatizing & discriminatory.
A variante Lambda: ela é mais infecciosa e escapa das vacinas? Virologista explica.
23 Jul, 2021 | 10:14hRelacionado: Lambda, the Newest WHO Variant of Interest, is Now in 29 Countries – Health Policy Watch
Estudo mostra que vacinas da AstraZeneca e da Pfizer são eficazes contra a variante Delta, mas são necessárias as duas doses.
22 Jul, 2021 | 13:08hComentários: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes E Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider
Relacionado: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. E Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. E Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
Comentário no Twitter
Public Health England's test-negative case-control study for Delta variant now in NEJM: over 14,000 people with Alpha, over 4,000 with Delta https://t.co/3l1QhKeXBT
Vax effectiveness against testing positive for Delta after 2 doses:
– BNT-Pfizer 88.0% (85-90)
– AZ 67.0% (61-72) pic.twitter.com/9UFy6CLSWw— Hilda Bastian, PhD (@hildabast) July 21, 2021
Anticorpos contra COVID-19 persistem por, pelo menos, 9 meses após a infecção – “98,8% das pessoas infectadas em fevereiro/março mostraram nível detectáveis de anticorpos em novembro.”
22 Jul, 2021 | 13:07hComunicado de imprensa: COVID-19 antibodies persist at least nine months after infection – Imperial College London
Estudo original: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications
Crianças devem tomar vacina contra COVID? O que diz a ciência.
22 Jul, 2021 | 13:05hShould children get COVID vaccines? What the science says – Nature
Análise mostra que os benefícios da vacinação contra COVID-19 pesam mais que os riscos de raros casos de miocardite.
22 Jul, 2021 | 13:04hComunicado de imprensa: Study finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis – American Heart Association
Estudo original: Myocarditis with COVID-19 mRNA Vaccines – Circulation
Comentário: Myocarditis and COVID-19 Vaccines: New Review Tackles Knowns, Unknowns – TCTMD
Comentário no Twitter
Just published ahead of print- Myocarditis with Covid mRNA Vaccines https://t.co/mc2yrr5pDV Mechanisms, benefit of COVID-19 mRNA vaccination over low risk, management strategies – review of all myocarditis cases published to date, CDC&other reports @PeterHotez @ishannovation
— BiykemBozkurt (@BiykemB) July 20, 2021